SVRA

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Savara Inc

NASDAQ | SVRA

6.29

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$1.28B

Market Cap

-

P/E Ratio

-0.53

EPS

$6.37

52 Week High

$1.89

52 Week Low

HEALTHCARE

Sector

SVRA Chart

Recent Chart
Price Action

SVRA Technicals

Tags:

SVRA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$78M
Total Revenue $0
Cost Of Revenue $78M
Costof Goods And Services Sold $78M
Operating Income -$103M
Selling General And Administrative $25M
Research And Development $78M
Operating Expenses $25M
Investment Income Net -
Net Interest Income $6.5M
Interest Income $6.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $130K
Income Before Tax -$96M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$96M
Comprehensive Income Net Of Tax -
Ebit -$102M
Ebitda -$102M
Net Income -$96M

Revenue & Profitability

Earnings Performance

SVRA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $213M
Total Current Assets $202M
Cash And Cash Equivalents At Carrying Value $15M
Cash And Short Term Investments $15M
Inventory -
Current Net Receivables $1M
Total Non Current Assets $11M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $10M
Intangible Assets Excluding Goodwill $10M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $181M
Other Current Assets $4.8M
Other Non Current Assets -
Total Liabilities $41M
Total Current Liabilities $15M
Current Accounts Payable $4.5M
Deferred Revenue -
Current Debt -
Short Term Debt $116K
Total Non Current Liabilities $27M
Capital Lease Obligations $116K
Long Term Debt $27M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $27M
Other Current Liabilities $10M
Other Non Current Liabilities $87K
Total Shareholder Equity $171M
Treasury Stock -
Retained Earnings -$489M
Common Stock $173K
Common Stock Shares Outstanding $198M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$89M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $130K
Capital Expenditures $25K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$40M
Cashflow From Financing $118M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$995K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$96M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$78M
Total Revenue $0
Cost Of Revenue $78M
Costof Goods And Services Sold $78M
Operating Income -$103M
Selling General And Administrative $25M
Research And Development $78M
Operating Expenses $25M
Investment Income Net -
Net Interest Income $6.5M
Interest Income $6.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $130K
Income Before Tax -$96M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$96M
Comprehensive Income Net Of Tax -
Ebit -$102M
Ebitda -$102M
Net Income -$96M

SVRA News

SVRA Profile

Savara Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Savara Inc. is a biopharmaceutical company based in Austin, Texas, specializing in the development of innovative therapies for rare lung diseases. Committed to addressing significant unmet medical needs in respiratory health, Savara's robust pipeline features several promising candidates targeting various orphan indications. By leveraging advanced scientific research and maintaining a patient-centric approach, Savara is well-positioned to make meaningful impacts in the treatment of lung diseases, establishing itself as a pivotal player in this niche therapeutic landscape.

LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
RUBI
-26.17%
$0.15
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.84%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
VEEE
+45.50%
$2.59
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
CAN
+9.78%
$1.01
AAPL
+0.46%
$278.85
AIIO
-9.09%
$0.70
NWTN
-9.09%
$0.70
AG
+12.73%
$15.23
WBD
+0.50%
$24.00
APLD
+8.66%
$27.10
NGD
+6.50%
$8.35
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.67%
$17.27
ITUB
+1.82%
$7.80
AGNC
+0.47%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
RUBI
-26.17%
$0.15
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.84%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
VEEE
+45.50%
$2.59
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
CAN
+9.78%
$1.01
AAPL
+0.46%
$278.85
AIIO
-9.09%
$0.70
NWTN
-9.09%
$0.70
AG
+12.73%
$15.23
WBD
+0.50%
$24.00
APLD
+8.66%
$27.10
NGD
+6.50%
$8.35
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.67%
$17.27
ITUB
+1.82%
$7.80
AGNC
+0.47%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.